 |
Justin Petrone is the editor of GenomeWeb's BioArray News and covers the microarray and biochip sector of the genomics market. E-mail Justin Petrone or follow his GenomeWeb Twitter account at @BioArrayNews. |
Team Uses Affy's OncoScan to Develop Prostate Cancer Prognostic Signature, Envisions Clinical Use
October 23, 2012
Team Uses Affy's OncoScan to Develop Prostate Cancer Prognostic Signature, Envisions Clinical Use
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- After Decade as CRO, Shanghai Biochip Plans Move into Chinese Molecular Dx Market
December 18, 2012 / BioArray News - Almac Dx Plans to Debut Array-based Colorectal Cancer-Recurrence Test Next Year
November 15, 2011 / BioArray News - Almac Diagnostics Sees Benefit for Test Pipeline in New Ovarian, Breast Cancer Studies
June 7, 2011 / BioArray News - Skyline Diagnostics Preps Leukemia Test for US Launch; Gains CE-IVD Mark
March 15, 2011 / BioArray News - Affymetrix Rolls Out OncoScan Service for Profiling FFPE Cancer Samples
September 28, 2010 / BioArray News